Working Papers in Economics,
University of Gothenburg, Department of Economics

Abstract: Should governments allow parallel trade of pharmaceuticals? There is no clear-cut answer to this question, since parallel trade causes some public concerns. One is that prices might not decrease much in the home country because consumers are price insensitive as a result of medical insurance. Another one is that consumers in the foreign country might face higher prices or supply shortages, since manufacturers want to deter parallel trade. And a third one is that consuming parallel imported drug, since it is perceived as inferior, creates additional cost. This paper provides answers to these concerns by taking into account the so-called healthcare reimbursement policy of reference pricing, requiring consumers to pay the full extra cost if they don’t buy the cheaper (parallel imported) alternative. It is then shown that parallel trade gives rise to more substantial price reductions under reference pricing than under coinsurance in the home (importing) country while, contrary to intuition, leaving price unchanged in the foreign (exporting) country. Even if parallel trade creates a social cost accrued from perceived quality difference, it would not be aggravated by reference pricing.

Keywords: Parallel Imports; Pharmaceuticals; Reference Pricing

JEL-codes: F13; I10; L12

35 pages, First version: June 17, 2009. Revised: May 1, 2011. Earlier revisions: January 5, 2011.

Full text files

20431 HTML file 

Download statistics

• University of Gothenburg, Department of Economics
• Ordering Working Papers
• Home page for this series

Questions (including download problems) about the papers in this series should be directed to Ann-Christin Räätäri Nyström ()
Report other problems with accessing this service to Sune Karlsson ().

This page generated on 2024-02-05 17:11:22.